Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03254927 · ClinicalTrials.gov registry record · Phase 2
A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma
A Phase 2 study, sponsored by Celldex Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT03254927 is a Phase 2 study that was terminated before completion, run by Celldex Therapeutics. The registered enrollment target is 30 participants.
The verdict
NCT03254927, a Phase 2 study, was terminated before completion, sponsored by Celldex Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
This is a study to determine the clinical benefit (how well the drug works), safety and tolerability of combining CDX-3379 and cetuximab. The study will enroll patients with advanced head and neck squamous cell carcinoma who have previously received cetuximab and progressed.
Interventions
- DRUG CDX-3379 and cetuximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2018-03-27 |
| Est. Completion | 2020-12-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03254927
The ClinicalTrials.gov registry entry for NCT03254927 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celldex Therapeutics, which has 42 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CDX-3379 and cetuximab is the first listed.
NCT03254927 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03254927 about?
NCT03254927 is a clinical study titled "A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma". This is a study to determine the clinical benefit (how well the drug works), safety and tolerability of combining CDX-3379 and cetuximab. The study will enroll patients with advanced head and neck squamous cell carcinoma who have previously received cetuximab and progressed.
What is the current status of trial NCT03254927?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2018-03-27. Estimated completion is 2020-12-16.
What interventions are being tested in trial NCT03254927?
The interventions under investigation include: CDX-3379 and cetuximab (DRUG).
Who is sponsoring clinical trial NCT03254927?
This trial is sponsored by Celldex Therapeutics, which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.